Europe: Resisting the Anticompetitive Crusade
It’s been another rocky few weeks for pharma in Europe. Particularly for big brand name companies. But necessity is proving the mother of invention, says Pharm Exec’s Brussels correspondent, Reflector....
View ArticleClik here to view.
EU Health Commissioner Emerges from the Dark
After a period of near invisibility, the EU’s health commissioner John Dalli has begun to make some higher profile appearance. Pharm Exec’s Europe correspondent Reflector assesses how these have been...
View Article"Data is the New Oil": Open Access to Sweep Europe?
The European Commission has followed the UK government’s plans to make all publicly funded scientific research available for free, announcing that it will improve access to scientific information in...
View ArticlePatients Wade into the European Pricing Debate
Patient groups are a growing force, not just in the debate around tactical areas of medical specialities, but also on the vital question of pricing and reimbursement rules. But will their voices be...
View ArticleEurope: Health Commissioner's Sudden Exit Spotlights Regulation Crisis
The sudden departure of EC Health Commissioner John Dalli tops an already difficult year for the European pharma regulators, writes Reflector. The abrupt departure of Health Commissioner John Dalli in...
View ArticleClinical Trials Caught in Fallout of EC Health Minister Departure
The abrupt departure of Europe’s health commissioner continues to resonate across the European Union – and to leave plans for new clinical trials legislation without a patron, writes Peter O’ Donnell...
View ArticleSaving Greece's Healthcare System: A Harbinger for Europe?
A just-published report from the European taskforce trying to help Greece crawl out of its crisis makes clear just how significant a role health reform is supposed to play in restoring health to the...
View ArticleEuropean Commission Investigates J&J, Novartis
By Stephanie Sutton. The European Commission claims that Johnson & Johnson and Novartis may have breached European antitrust rules. The EC has issued a Statement of Objections, a formal step in the...
View ArticleEurope: Is National Drug Pricing Freedom Nearing its Expiry Date?
By Reflector, Brussels correspondent. For more than fifty years the basic European Union rules about medicines have been clear. Each member country is free to decide the prices that medicines are sold...
View ArticleEurope: Countdown Time for the Innovative Medicines Initiative?
Momentum is gathering in Brussels for real battles over carving up the 1 trillion dollars that the European Union has now agreed to spend between the end of this year and the end of the decade. The...
View ArticleClik here to view.
European Pharma Gears Up for Horizon 2020
European Pharma Gears Up for Horizon 2020 The ink is not yet dry on the European Union’s Horizon 2020 agreement to invest some €70 billion ($92 bn) in research over the next seven years, and already...
View ArticleEurope's Mooted 'Passport for Physicians': Implications for Patients
Europe moved one step closer to a passport for physicians in early October. The European Parliament gave its backing to creating a virtual professional qualifications card that will allow doctors,...
View ArticleEurope: Whatever Happened to Faster Reimbursement for Generics?
The plan to accelerate generic pricing and reimbursement has become another tragic European casualty, writes Brussels correspondent Reflector. Another of those anniversaries in European pharmaceutical...
View ArticleClik here to view.
EU Blocks Further Limits on Human Embryo Research, Backlash Hits
By Peter O’ Donnell, Applied Clinical Trials. A European bid to impose additional limits on research involving human embryos has been defeated. European Union officials decided last week (May 28) that...
View ArticleEuropean Pharma Policy Reaches "New Level of Timidity"
By Peter O’ Donnell, Applied Clinical Trials. The European Union has managed to snatch defeat from the jaws of opportunity once more! A long-heralded document portentously entitled “Pharmaceutical...
View ArticleFurther Boost for Europe’s Largest Healthcare Partnership
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced the launch of IMI2, with a budget of €3.3 billion (US$ 4.5 bn). IMI (the Innovative Medicines Initiative) is...
View ArticleEuropean Pharma Races to Catch Up with Data Protection
The European Union’s struggle to bring its data protection rules into the 21st century continues—haltingly—as the EU itself enters its new era, with a new European Parliament, a new President-designate...
View Article
